Journal
DRUG DELIVERY AND TRANSLATIONAL RESEARCH
Volume 12, Issue 1, Pages 229-239Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s13346-021-00902-z
Keywords
Besifloxacin; Ocular; Nanoemulsion; Permeation study
Funding
- Hamadan University of Medical Sciences, Hamadan, I.R. Iran [9704192161]
Ask authors/readers for more resources
This study successfully developed nanoemulsions containing besifloxacin for ocular drug delivery. Through a series of evaluations and tests, it was shown to have good potential for application in ocular administration and could be considered as a suitable alternative for treating bacterial eye infections.
The purpose of this study was to develop and evaluate nanoemulsions (NEs) containing besifloxacin for ocular drug delivery. Pseudo ternary phase diagrams were constructed using Triacetin (oil), Cremophor(R) RH 40 (surfactant), and Transcutol(R)P (co-surfactant) to identify NE regions. Six formulations were developed by low-energy emulsification method and then evaluated for size, refractive index, pH, osmolality, viscosity, and drug release. After accelerated physical stability and bovine conrneal permeation studies, NE2 was chosen as optimized formulation forantimicrobial efficacy, and hen's egg test-chorioallantoic membrane (HET-CAM) tests. The particle size of optimum NE was 14 nm with a narrow size distribution. Moreover, other physicochemical characterizations were in the acceptable range for ocular administration. Besifloxacin-loaded NEs demonstrated sustained release pattern and 1.7-fold higher permeation compared with the control suspension in the ex vivo transcorneal permeation study. HET-CAM test indicated no irritation, and HL% revealed no damage to the tissue, so the optimum NE is well tolerated by the eye. In vitro antimicrobial evaluation, showed comparative efficacy of lower drug-loaded NE (0.2%) versus 0.6% besifloxacin suspension (equal concentration to commercial besifloxacin eye drop). In conclusion, besifloxacin-loaded NEs could be considered as a suitable alternative to the marketed suspension for treating bacterial eyeinfections.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available